Answering Pivotal Questions in the Diagnosis and Treatment of Primary Biliary Cirrhosis and Non-Alcoholic Steatohepatitis

Symposium Report from the Intercept Pharmaceuticals, Inc. Supported Satellite Symposium, held at the International Liver Congress™ 2015, the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 22nd–26th April 2015

Chairperson: Michael Trauner1
Speakers: David E.J. Jones,2 Vlad Ratziu3

1. Medical University of Vienna, Vienna, Austria
2. Newcastle University, Newcastle upon Tyne, UK
3. Hôspital Pitié-Salpêtrière Université Pierre et Marie Curie, Paris, France

Disclosure: Michael Trauner has consulted for AbbVie, Albireo Pharma, Falk Pharma, Gilead, Intercept Pharmaceuticals, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and Phenex Pharmaceuticals; and has received speaker honoraria from Falk Pharma, Genfit, and Merck Sharp & Dohme Corp. David E.J. Jones has consulted for GSK, Pfizer, and Intercept Pharmaceuticals; has received research funding (to UK-PBC) from Intercept Pharmaceuticals, GSK, and Lumena; and has received speaker honoraria from Falk Pharma. Vlad Ratziu has consulted for Intercept Pharmaceuticals, Genfit, Tobira, and Galmed.
Acknowledgements: Writing assistance was provided by Dr Ewen Legg of Halcyon Medical Writing.
Support: Medical writing assistance was funded by Intercept Pharmaceuticals, Inc. The views and opinions expressed are those of the authors as stated during the symposium and are not necessarily those of Intercept Pharmaceuticals, Inc.
Citation: EMJ Hepatol. 2015;3[2]:52-59.

Meeting Summary

Professor Trauner introduced the subject of liver disease and its burden within the European Union (EU) and across the globe. Professor Jones summarised the progress made in understanding the pathophysiology of primary biliary cirrhosis (PBC), current unmet needs in the ursodeoxycholic acid (UDCA) era, and novel therapeutic options for PBC treatment. Professor Ratziu discussed the emerging understanding of the complex multisystem pathophysiology of non-alcoholic steatohepatitis (NASH), summarised the available therapeutic targets, and detailed the trials of novel agents currently underway.

Download (PDF, 113KB)

Comments are closed.